Due to ERG capacity constraints, we are rescheduling the timeline for the appraisal of Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer following the receipt of submissions in mid-February 2022. We will continue to assess the ERG capacity, and if an earlier slot becomes available, we will look to bring this topic forwards.
We anticipate that the appraisal will restart in mid-March 2022 when the submissions are sent over to the Evidence Review Group (ERG) and will be discussed at committee in early October 2022.